General Workshop Documents
2019 Meeting Report published in Translational Medicine Communications: Prevent Cancer Foundation quantitative CT imaging workshop XVI: lung cancer, COPD and cardiovascular disease – on the cusp of transformation, Arlington, VA
American Lung Association One-Pager
Workshop Video Content and Materials
Included below are the full session recordings accompanied by topic overview videos and slides for those speakers who used them. There were speakers and session topics for which presentation slides were not used.
Session One: Welcome, National Leadership Award & Keynote Address
Session Two: Value of Metrology
Session Three: Ensuring Health Equity in Lung Cancer Screening & Management
Session Four: Lung Cancer Screening & COPD – Clinical Interventions & Implications
Session Five: COPD & Small Lung Nodule – Technical Applications
Session Seven: Population Health Metrics – HEDIS & Stars
Session One: Welcome, National Leadership Award & Keynote Address
Welcome and Overview – James L. Mulshine, M.D., Rush University Medical Center
James L. Mulshine, M.D. Leadership Award – Presentation to Dr. Daniel Sullivan
Foundation stories: 35 years of cancer research and impact
Keynote – Swatee Surve, MBA, MSME, Founder & Chief Executive Officer, Litesprite
Can We Use Games to Collect High Quality Data to Improve Health Outcomes for Screening-Detected Chronic Health Conditions?
Session Two: Value of Metrology
Topic 1: Clinical Perspective: What are the Challenges and Hurdles Hindering the Implementation of Advanced Image Analysis Tools for CT Screening?
Topic overview: Gregory Sorensen, MD, DeepHealth, Inc.
Panelist Slides
Ronald Summers, MD, PhD, National Institutes of Health Clinical Center
Curtis Langlotz, MD, PhD, Stanford University Medical Center
Topic 2: Metrology and Quality Assurance Perspective: What are the Challenges and Hurdles Hindering the Validation and Regulatory Approval of AI Algorithms for CT Screening?
Topic Overview: Maryellen L. Giger, PhD, The University of Chicago
Panelist Slides
Nancy Obuchowski, PhD, Cleveland Clinic Foundation
Ricardo Avila, MS, Accumetra LLC
Anthony P. Reeves, PhD, School of Electrical and Computer Engineering, Cornell University
Timor Kadir, DPhil, MEng, Optellum (United Kingdom)
Session Three: Ensuring Health Equity in Lung Cancer Screening & Management
Topic 1: Addressing Health Equity in Vulnerable Communities
Topic 2: Can Information Technologies Enhance Access to Health Information for Vulnerable Communities?
Topic Overview: Garth Graham, MD, MPH, FACP, FACC, CVS Health
Session Four: Lung Cancer Screening & COPD – Clinical Interventions & Implications
Topic 1: Technical Perspective: Can the Low Dose CT Scan Be Used as a Window to Early Lung Disease?
Topic Overview: Lee Gazourian, MD, Lahey Hospital & Medical Center
Panelist Slides
Marcus Chen, MD, Cardiothoracic CT Program, National Heart, Lung and Blood Institute
Mary Salvatore, MD, MBA, Division of Cardiothoracic Imaging, Columbia University Medical Center
Topic 2: Clinical Perspective: Moving to Pulmonary Disease Interception
Topic Overview: Gerard Criner, MD, FACP, FACCP, Lewis Katz School of Medicine, Temple University
Panelist Slides
Bartolome Celli, MD, FCCP, Chronic Obstructive Pulmonary Disease Center, Brigham and Women’s Hospital and Harvard Medical School
Barry Make, MD, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health
Session Five: COPD & Small Lung Nodule – Technical Applications
Topic 1: Improving the Impact of the QIBA CT Small Lung Nodule Profile
Topic Overview: Ricardo Avila, MS, Accumetra LLC
Panelist slides
Nancy Obuchowski, PhD, Cleveland Clinic Foundation
Raja Subramaniam, PhD, Icahn School of Medicine at Mount Sinai
Samuel Armato, PhD, The University of Chicago
Topic 2: Making Progress Toward a COPD & Small Lung Nodule Protocol
Topic Overview: George R. Washko, MMSc, MD, Brigham and Women’s Hospital and Harvard Medical School
Panelist slides
Sean Fain, PhD, University of Wisconsin School of Medicine and Public Health
Session Six: IELCART
IELCART Update on Lung Cancer Screening Innovations
Claudia I. Henschke, PhD, MD, Icahn School of Medicine at Mount Sinai
Treatment of Early Stage Lung Cancer and How to Identify Which Cancers are Most Curable Versus Those Likely to Recur
Topic Overviews
David Yankelevitz, MD, Icahn School of Medicine at Mount Sinai
Nasser K. Altorki, MD, Division of Thoracic Surgery, New York Presbyterian-Weill Cornell Medical Center
Panelist Slides
Targeted Therapy Trial for Aggressive Early Stage Lung Cancer
Topic Overview: Rajwanth Veluswamy, MD, MSCR, Icahn School of Medicine at Mount Sinai
Session Seven: Population Health Metrics – HEDIS & Stars
Topic 1: Lessons from Population Health: How Quality Metrics Work
Introduction from Moderator: Bruce S. Pyenson, FSA, MAAA, Milliman, Inc.
Topic Overviews
Mary Barton, MD, MPP, Performance Measurement, National Committee for Quality Assurance
Robert A. Smith, PhD, Cancer Screening, American Cancer Society and National Lung Cancer Roundtable
Hannah Green, MPH, Health Policy, American Lung Association
Topic 2: How would Providers and Payers Respond to a Population Health Metric for Lung Cancer Screening?
Virtual Breakout Sessions
The Quantitative Imaging Workshops have hosted discussions on specific topics where there is shared interest in advancing progress. Our process attempts to explore key topics relative to opportunities and challenges. We ask content experts to weigh in on refining issues from their perspectives. From these discussions we look to distill action plans on how we can have the greatest impact on moving a field further. A critical aspect of this process is the vetting of candidate issues by the full assembly of workshop participants which takes place in these breakout sessions.
2020 Topics:
- Defining and Managing CT Screening Findings of Early Lung Diseases
- Approach to Advancing Combined Modality Therapy for Early Stage Screen-Detected Disease—Adjuvant/Neoadjuvant Therapy
Day 1 – Joint Session: Breakout Introduction
Day 2 – Two Simultaneous Sessions
Topic 1: Defining and Managing CT Screening Findings of Early Lung Diseases
Topic 2: Approach to Advancing Combined Modality Therapy for Early Stage Screen-Detected Disease—Adjuvant/Neoadjuvant Therapy
Day 3 – Joint Session: Results & Action Plans
Topic 1: Defining and Managing CT Screening Findings of Early Lung Diseases – Final Summary Slides
Special thanks to the 2020 Quantitative Imaging Workshop supporters!
American Cancer Society
Amgen
AstraZeneca
Genentech
Helsinn
GO2 Foundation
